Erratum to: Evaluation of cetuximab as a candidate for targeted a-particle radiation therapy of HER1-positive disseminated intraperitoneal disease, mAbs, Volume 7, Issue 1, pages 255–264, 10.4161/19420862.2014.985160;Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease

mAbs

Volumn 7, Issue 1, 2015, Pages 255-264

  Milenic, Diane E ^a   Baidoo, Kwamena E ^a   Kim, Young Seung ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

212 Pb; Cetuximab; HER1; Radioimmunotherapy; particle

Indexed keywords

CARBOPLATIN; CETUXIMAB; CETUXIMAB PB 212; GEMCITABINE; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB PB 212; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOTOPE; MONOCLONAL ANTIBODY; RADIOSENSITIZING AGENT;

ALPHA RADIATION; ANIMAL EXPERIMENT; ARTICLE; CANCER PATIENT; DISSEMINATED INTRAPERITONEAL DISEASE; DRUG EFFICACY; LIVER; MOUSE; NONHUMAN; PERITONEAL DISEASE; RADIOIMMUNOASSAY; SPLEEN; SURVIVAL; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; HUMAN; NUDE MOUSE; PERITONEAL NEOPLASMS; PROCEDURES; RADIOIMMUNOTHERAPY; TUMOR CELL LINE;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEOXYCYTIDINE; HUMANS; ISOTOPES; MICE; MICE, NUDE; PERITONEAL NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84921340579     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1116915     Document Type: Erratum

References (56)

1. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004; 10:7834-41; PMID:15585615; http://dx.doi.org/10.1158/1078-0432.CCR-04-1226
2. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005; 20:557-68; PMID:16248771; http://dx.doi.org/10.1089/cbr.2005.20.557
3. Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW. Evaluation of platinum chemotherapy in combination with HER2-targeted alpha-particle radiation. Cancer Biother Radiopharm 2013; 28:441-9; PMID:23758610; http://dx.doi.org/10.1089/cbr.2012.1423
4. Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, Brechbiel MW. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 2007; 13:1926-35; PMID:17363549; http://dx.doi.org/10.1158/1078-0432.CCR-06-2300
5. Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ, Flynn J, Brechbiel MW. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 2008; 14:5108-15; PMID:18698028; http://dx.doi.org/10.1158/1078-0432.CCR-08-0256
6. Howell RW, Azure MT, Narra VR, Rao DV. Relative biological effectiveness of alpha-particle emitters in vivo at low doses. Radiat Res 1994; 137:352-60; PMID:8146279; http://dx.doi.org/10.2307/3578710
7. Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol 2013; 40:592-9; PMID:23602604; http://dx.doi.org/10.1016/j.nucmedbio.2013.01.010
8. Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm 2014; 29:12-7; PMID:24229395; http://dx.doi.org/10.1089/cbr.2013.1531
9. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 2012; 11:639-48; PMID:22238365; http://dx.doi.org/10.1158/1535-7163.MCT-11-0671
10. Yong KJ, Milenic DE, Baidoo KE, Kim YS, Brechbiel MW. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograftmodel. Cancer Med 2013; 2:646-53; PMID:24403230
11. Agus DB, Bunn PA, Jr., Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27:53-63; discussion 92-100.
12. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45:457-61; PMID:1968437; http://dx.doi.org/10.1002/ijc.2910450314
13. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19:554-68; PMID:11458821; http://dx.doi.org/10.1081/CNV-100103852
14. Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ, Jr. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 2012; 7:e49829; PMID:23189165
15. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11:689-708; PMID:15613446; http://dx.doi.org/10.1677/erc.1.00600
16. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94:1593-611; PMID:11920518; http://dx.doi.org/10.1002/cncr.10372
17. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13:506-13; PMID:11673692; http://dx.doi.org/10.1097/00001622-200111000-00014
18. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025
19. Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004; 5:1621-33; PMID:15212612; http://dx.doi.org/10.1517/14656566.5.7.1621
20. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8; PMID:18003960; http://dx.doi.org/10.1056/NEJMoa071834
21. Guo Y, Parry JJ, Laforest R, Rogers BE, Anderson CJ. The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer. J Nucl Med 2013; 54:1621-9; PMID:23873478; http://dx.doi.org/10.2967/jnumed.112.118539
22. Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F. Lu-Labeled Antibodies for EGFR-.Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model. Mol Pharm 2014; 11: 800-807; http://dx.doi.org/10.1021/mp4005047
23. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008; 23:619-31; PMID:18999934; http://dx.doi.org/10.1089/cbr.2008.0493
24. Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Ycetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS One 2011; 6: e18198; PMID:21464917; http://dx.doi.org/10.1371/journal.pone.0018198
25. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A"-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010; 37:1368-76; PMID:20155263; http://dx.doi.org/10.1007/s00259-009-1370-z
26. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177) Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46:1898-906; PMID:16269605
27. Gaffar SA, Pant KD, Shochat D, Bennett SJ, Goldenberg DM. Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon-specific antigen-p (CSAp). Int J Cancer 1981; 27:101-5; PMID:7251228; http://dx.doi.org/10.1002/ijc.2910270116
28. Hillairet de Boisferon M, Raguin O, Dussaillant M, Rostene W, Barbet J, Gruaz-Guyon A. Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens. Bioconjug Chem 2000; 11:452-60; PMID:10898565; http://dx.doi.org/10.1021/bc9901090
29. Hillairet De Boisferon M, Raguin O, Thiercelin C, Dussaillant M, Rostene W, Barbet J, Pelegrin A, Gruaz-Guyon A. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model. Bioconjug Chem 2002; 13:654-62; PMID:12009958; http://dx.doi.org/10.1021/bc015585g
30. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumorassociated glycoprotein 72. Cancer 2010; 116:1059-66; PMID:20127951; http://dx.doi.org/10.1002/cncr.24793
31. Munz DL, Alavi A, Koprowski H, Herlyn D. Improved radioimmunoimaging of human tumor xenografts by a mixture of monoclonal antibody F(ab')2 fragments. J Nucl Med 1986; 27:1739-45; PMID:3772507
32. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78; PMID:16467544; http://dx.doi.org/10.1056/NEJMoa053422
33. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-8; PMID:19897418; http://dx.doi.org/10.1016/S1470-2045(09)70311-0
34. Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008; 72:534-42; PMID:18793955; http://dx.doi.org/10.1016/j.ijrobp.2008.06.1490
35. Koi L, Bergmann R, Bruchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiother Oncol 2014;110:362-9; PMID:24440046; http://dx.doi.org/10.1016/j.radonc.2013.12.001
36. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med 2010; 51:942-50; PMID:20484421; http://dx.doi.org/10.2967/jnumed.109.071290
37. Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010; 16:2095-105; PMID:20215534; http://dx.doi.org/10.1158/1078-0432.CCR-09-2495
38. Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G. Targeting aberrant DNA double-strand break repair in triplenegative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther 2013; 12:2043-54; PMID:23873849; http://dx.doi.org/10.1158/1535-7163.MCT-13-0108
39. Guerard F, Lee YS, Brechbiel MW. Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV). Chemistry 2014; 20:5584-91; PMID:24740517; http://dx.doi.org/10.1002/chem.201304115
40. Guerard F, Lee YS, Tripier R, Szajek LP, Deschamps JR, Brechbiel MW. Investigation of Zr(IV) and 89Zr (IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem Commun (Camb) 2013; 49:1002-4; PMID:23250287; http://dx.doi.org/10.1039/c2cc37549d
41. Hand PH, Nuti M, Colcher D, Schlom J. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res 1983; 43:728-35; PMID:6848188
42. Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted alpha-particle radiation therapy. Clin Cancer Res 2013; 19:530-7; PMID:23230321; http://dx.doi.org/10.1158/1078-0432.CCR-12-0298
43. Hei TK, Wu LJ, Liu SX, Vannais D, Waldren CA, Randers-Pehrson G. Mutagenic effects of a single and an exact number of alpha particles in mammalian cells. Proc Natl Acad Sci U S A 1997; 94:3765-70; PMID:9108052; http://dx.doi.org/10.1073/pnas.94.8.3765
44. Pugliese M, Durante M, Grossi GF, Monforti F, Orlando D, Ottolenghi A, Scampoli P, Gialanella G. Inactivation of individual mammalian cells by single alpha-particles. Int J Radiat Biol 1997; 72:397-407; PMID:9343105; http://dx.doi.org/ 10.1080/095530097143176
45. Soyland C, Hassfjell SP. Survival of human lung epithelial cells following in vitro alpha-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells. Int J Radiat Biol 2000; 76:1315-22; PMID:11057739; http://dx.doi.org/10.1080/09553000050151583
46. Li Y, Abbas Rizvi SM, Blair nee Brown JM, Cozzi PJ, Qu CF, Ow KT, Tam PN, Perkins AC, Russell PJ, Allen BJ. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. Int J Radiat Oncol Biol Phys 2004; 60:896-908; PMID:15465208; http://dx.doi.org/10.1016/j.ijrobp.2004.04.035
47. Li Y, Cozzi PJ, Qu CF, Zhang DY, Abbas Rizvi SM, Raja C, Allen BJ. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate. Cancer Lett 2004; 205:161-71; PMID:15036648; http://dx.doi.org/10.1016/j.canlet.2003.10.035
48. Wang J, Abbas Rizvi SM, Madigan MC, Cozzi PJ, Power CA, Qu CF, Morgenstern A, Apostolidis C, Russell PJ, Allen BJ, et al. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate 2006; 66:1753-67; PMID:16955401; http://dx.doi.org/10.1002/pros.20502
49. Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, Brechbiel MW. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010; 2:550-64; PMID:20716957; http://dx.doi.org/10.4161/mabs.2.5.13054
50. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976; 12:180-91; PMID:1262041; http://dx.doi.org/ 10.1007/BF02796440
51. Garmestani K, Yao Z, Zhang M, Wong K, Park CW, Pastan I, Carrasquillo JA, Brechbiel MW. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl Med Biol 2001; 28:409-18; PMID:11395314; http://dx.doi.org/10.1016/S0969-8051(00)00203-1
52. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, Carrasquillo JA, Pastan I, Brechbiel MW. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem 1997; 5:1925-34; PMID:9370037; http://dx.doi.org/10.1016/S0968-0896(97)00130-2
53. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-75; PMID:14907713
54. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999; 26:977-82; PMID:10708314; http://dx.doi.org/10.1016/S0969-8051(99)00054-2
55. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 1992; 3:342-5; PMID:1390990; http://dx.doi.org/10.1021/bc00016a014
56. Ray GL, Baidoo KE, Wong KJ, Williams M, Garmestani K, Brechbiel MW, Milenic DE. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol 2009; 157:1541-8; PMID:19681874; http://dx.doi.org/10.1111/j.1476-5381.2009.00327.x